Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. Academic Article uri icon

Overview

abstract

  • Systemic onset juvenile idiopathic arthritis (SoJIA) encompasses approximately 10% of cases of arthritis that begin in childhood. The disease is unique in terms of clinical manifestations, severity of joint involvement, and lack of response to tumor necrosis factor blockade. Here, we show that serum from SoJIA patients induces the transcription of innate immunity genes, including interleukin (IL)-1 in healthy peripheral blood mononuclear cells (PBMCs). Upon activation, SoJIA PBMCs release large amounts of IL-1beta. We administered recombinant IL-1 receptor antagonist to nine SoJIA patients who were refractory to other therapies. Complete remission was obtained in seven out of nine patients and a partial response was obtained in the other two patients. We conclude that IL-1 is a major mediator of the inflammatory cascade that underlies SoJIA and that this cytokine represents a target for therapy in this disease.

publication date

  • April 25, 2005

Research

keywords

  • Arthritis, Juvenile
  • Gene Expression Regulation
  • Interleukin-1
  • Prednisone
  • Sialoglycoproteins

Identity

PubMed Central ID

  • PMC2213182

Scopus Document Identifier

  • 18644385243

Digital Object Identifier (DOI)

  • 10.1084/jem.20050473

PubMed ID

  • 15851489

Additional Document Info

volume

  • 201

issue

  • 9